Probable Novel APP Met671Leu Mutation in a Chinese Han Family with Early-Onset Alzheimer's Disease
- PMID: 38504005
- DOI: 10.1007/s12017-023-08770-1
Probable Novel APP Met671Leu Mutation in a Chinese Han Family with Early-Onset Alzheimer's Disease
Abstract
Familial Alzheimer's disease (AD) is a rare disease caused by autosomal-dominant mutations. APP (encoding amyloid precursor protein), PSEN1 (encoding presenilin 1), and PSEN2 (encoding presenilin 2) are the most common genes cause dominant inherited AD. This study aimed to demonstrate a Chinese early-onset AD pedigree presenting as progressive memory impairment, apraxia, visual-spatial disorders, psychobehavioral disorders, and personality changes with a novel APP gene mutation. The family contains four patients, three carries and three normal family members. The proband underwent brain magnetic resonance imaging (MRI), 18F-fludeoxyglucose positron emission tomography (18F-FDG-PET), cerebrospinal fluid amyloid detection, 18F-florbetapir (AV-45) Positron Emission Computed Tomography (PET) imaging, whole-exome sequencing and Sanger sequencing. Brain MRI images showed brain atrophy, especially in the entorhinal cortex, temporal hippocampus, and lateral ventricle dilation. The FDG-PET showed hypometabolism in the frontotemporal, parietal, and hippocampal regions. 18F-florbetapir (AV-45) PET imaging showed cerebral cortex Aβ protein deposition. The cerebrospinal fluid amyloid protein test showed Aβ42/Aβ40 ratio decreases, pathological phosphor-tau level increases. Whole-exome sequencing detected a new missense mutation of codon 671 (M671L), which was a heterozygous A to T point mutation at position 2011 (c.2011A > T) in exon 16 of the amyloid precursor protein, resulting in the replacement of methionine to Leucine. The co-separation analysis was validated in this family. The mutation was found in 3 patients, 3 clinical normal members in the family, but not in the other 3 unaffected family members, 100 unrelated normal subjects, or 100 sporadic patients with AD. This mutation was probably pathogenic and novel in a Chinese Han family with early-onset AD.
Keywords: APP; Alzheimer’s disease; Biomarker; EOAD.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Longitudinal Evolution of Financial Capacity and Cerebral Tau and Amyloid Burden in Older Adults with Normal Cognition or Mild Cognitive Impairment.J Prev Alzheimers Dis. 2024;11(4):966-974. doi: 10.14283/jpad.2023.121. J Prev Alzheimers Dis. 2024. PMID: 39044507 Free PMC article.
-
Patterns and severity of vascular amyloid in Alzheimer's disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer's disease.Acta Neuropathol. 2018 Oct;136(4):569-587. doi: 10.1007/s00401-018-1866-3. Epub 2018 May 16. Acta Neuropathol. 2018. PMID: 29770843 Free PMC article.
-
Transmissible long-term neuroprotective and pro-cognitive effects of 1-42 beta-amyloid with A2T icelandic mutation in an Alzheimer's disease mouse model.Mol Psychiatry. 2024 Dec;29(12):3707-3721. doi: 10.1038/s41380-024-02611-8. Epub 2024 Jun 14. Mol Psychiatry. 2024. PMID: 38871852 Free PMC article.
-
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer's disease.Expert Opin Biol Ther. 2024 Nov;24(11):1261-1269. doi: 10.1080/14712598.2024.2416947. Epub 2024 Nov 12. Expert Opin Biol Ther. 2024. PMID: 39432414 Review.
-
Cognitive Outcomes in Autosomal-Dominant Alzheimer's Disease: A Comprehensive Review from a Colombian Kindred with the Presenilin-1 E280A Mutation.J Alzheimers Dis. 2024;101(2):397-415. doi: 10.3233/JAD-240360. J Alzheimers Dis. 2024. PMID: 39213071 Free PMC article. Review.
References
-
- Arvanitakis, Z., Shah, R. C., & Bennett, D. A. (2019). Diagnosis and management of dementia: Review. JAMA, 322(16), 1589–1599. https://doi.org/10.1001/jama.2019.4782 - DOI - PubMed - PMC
-
- Ayodele, T., Rogaeva, E., Kurup, J. T., Beecham, G., & Reitz, C. (2021). Early-onset Alzheimer’s disease: What is missing in research? Current Neurology and Neuroscience Reports, 21(2), 4. https://doi.org/10.1007/s11910-020-01090-y - DOI - PubMed - PMC
-
- Bagyinszky, E., Kang, M. J., Van Giau, V., Shim, K., Pyun, J. M., Suh, J., An, S. S. A., & Kim, S. (2019). Novel amyloid precursor protein mutation, Val669Leu (“Seoul APP”), in a Korean patient with early-onset Alzheimer’s disease. Neurobiology of Aging, 84(231), 236. https://doi.org/10.1016/j.neurobiolaging.2019.08.026 - DOI
-
- Ben, K. N., Tyteca, D., Marinangeli, C., Depuydt, M., Collet, J. F., Courtoy, P. J., Renauld, J. C., Constantinescu, S., Octave, J. N., & Kienlen-Campard, P. (2012). Structural features of the KPI domain control APP dimerization, trafficking, and processing. FASEB Journal, 26(2), 855–867. https://doi.org/10.1096/fj.11-190207 - DOI
-
- Bolos, M., Hu, Y., Young, K. M., Foa, L., & Small, D. H. (2014). Neurogenin 2 mediates amyloid-beta precursor protein-stimulated neurogenesis. Journal of Biological Chemistry, 289(45), 31253–31261. https://doi.org/10.1074/jbc.M114.581918 - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical